On Monday, CME Group Cl A earned an upgrade to its Relative Strength (RS) Rating, from 67 to 71.
This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks matched up against all other stocks.
History reveals that the stocks that go on to make the biggest gains tend to have an 80 or better RS Rating as they launch their biggest climbs. See if CME Group Cl A can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
CME Group Cl A is now considered extended and out of buy range after clearing a 223.80 buy point in a first-stage flat base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Taking a look at revenue and profit performance, CME Group Cl A has posted rising EPS growth over the last two quarters. Sales growth has also increased during the same period.
The company holds the No. 4 rank among its peers in the Financial Services-Specialty industry group. Marex Group is the No. 1-ranked stock within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
